Reuters Health News Feed
Reuters: Health News
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals.
WASHINGTON (Reuters) - House Republicans were making headway in efforts to build support for a reworked plan to overhaul the U.S. healthcare system, but have not decided when to vote, House Speaker Paul Ryan said on Thursday.
(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Bayer AG's drug Stivarga to treat liver cancer, the first such approval in nearly a decade.
SEOUL (Reuters) - South Korea said on Thursday it has fined Swiss drugmaker Novartis 55.1 billion won ($48.80 million) for offering doctors kickbacks to recommend the company's drugs, and also suspended insurance coverage for some of its drugs.
(Reuters Health) - Despite increased attention to deaths and injuries resulting from clashes with police, U.S. emergency department visits for police-associated injuries have remained stable at about 51,000 a year since 2006, researchers say.
Reuters Health) - Exposing babies to puppies and other furry pets might help them accumulate two types of bacteria in their gut that are associated with a lower risk of allergies and obesity, a Canadian study suggests.
(Reuters Health) - College is increasingly a gateway for young adults in the U.S. to begin using marijuana and the risk keeps growing the more “normalized” pot use becomes, researchers say.
(Reuters) - The U.S. Food and Drug Administration said on Thursday it had approved Biomarin Pharmaceutical Inc's drug to treat a type of Batten disease, an extremely rare disorder that mainly impacts the nervous system.
(Reuters Health) - Older adults who want to get moving to help boost their brain function have a wide variety of workouts to choose from, a research review suggests.
ZURICH (Reuters) - Swiss drugmaker Roche, encouraged by better than expected first-quarter sales, said it was confident new drugs will help to deliver revenue and profit growth even as its older medicines take a hit from cheaper copies.
LONDON (Reuters) - British biotech firm Synairgen lost nearly half its value on Thursday as partner AstraZeneca pulled the plug on an experimental drug designed to help patients fight common cold viruses.